We previously identified that greater frequency and duration of gaps in CGM wear period were associated with lower time in range (TIR) in adults with T2D. The current study explored impact of CGM wear period on glycemic metrics by diabetes type in adult and pediatric users.
Random samples of 1000 Dexcom G6 users each from June 2022 were pulled for T2D adults (≥18 years), T1D adults (≥18), and T1D pediatrics (<18). T2D pediatric cohort was excluded due to data insufficiency. Gaps in CGM wear period >3 days defined as extended gaps (EGs) were observed over 3 months. Comparisons were made between users with and without ≥1 EG. Regression models estimated the effects of EGs and cohorts on CGM metrics.
Overall, sample reported a high median [IQR] CGM wear time (96% [86, 99]). EGs were present in only 31% of users. T2 adults had 1.8 (95% CI: 1.5 - 2.2) times greater odds than T1 adults and 2.3 (1.9 - 2.8) times greater odds than T1 pediatrics to have EGs (Table). After adjusting for cohorts, presence of EGs was significantly associated with 9% (8 - 11) lower TIR and 0.4% (0.3 - 0.5) greater GMI. Significant associations were also identified with time above range, mean glucose, and coefficient of variation.
Odds of EGs varied by diabetes type and age. T2 adults had the greatest odds of EGs, which were associated with less optimal CGM metrics. These results suggest that uninterrupted CGM access may result in beneficial glycemic outcomes.
C. Hicks: Employee; Dexcom, Inc. M.A. Crawford: Employee; Dexcom, Inc. H. Singh: Employee; Dexcom, Inc.
